Date & time
4:45 p.m. – 7 p.m.
In-person
4TH SPACE
J.W. McConnell Building
1400 De Maisonneuve Blvd. W.
Room LB 103
Yes - See details
Mark International Accounting Day by exploring the future of the accounting profession with a moderated panel discussion, followed by a networking reception.
Ahmad Hammami, Interim Chair of Concordia’s Department of Accounting welcomes distinguished John Molson School alumni and industry leaders whose insights and experience will inspire and engage the next generation of accounting professionals. The evening will feature a moderated panel discussion, followed by networking.
This first-time event will spotlight emerging trends shaping industry and practice, with a focus on two themes; the evolving role of CPAs in advancing sustainable business practices and the potential for using artificial intelligence in the profession.
We hope you could join us to explore how we are redefining what counts—and how to count it!
Michel Magnan, PhD, FRSC, FCPA Auditor, FCA, ASC, C.Dir
Distinguished University Research Professor, Accountancy
Stephen A. Jarislowsky Chair in Corporate Governance
Tania Tanic, CPA, ASC, C.DIR. EMBA
Founder and CEO, BrainStorm CyberRisk
Steve Forte, CPA, CMA , BComm 01
President, CEO, CFO of Repare Therapeutics
Jack Martin, CPA Auditor, CISA, CA•IFA, CFF, BComm 99
Partner and National Leader, Forensic Data Analytics at KPMG in Canada
We strive to host inclusive, accessible events that enable all individuals, including individuals with disabilities, to engage fully. If you require disability-related accommodations, please contact alumnievents@concordia.ca by November 7 to allow us time to coordinate your request.
Michel Magnan holds a PhD in Business Administration from the University of Washington and is a Fellow Chartered Professional Accountant (FCPA). His research focuses on financial reporting, governance, executive compensation, corporate social responsibility, and sustainability.
A member of the Royal Society of Canada, Magnan has published over 150 papers and presented his work globally. He serves on the board of Desjardins Group and is a trustee of the Concordia University Employees Retirement Plan. His academic and professional contributions have earned him several prestigious awards, including the Yvan Allaire Medal of Governance in 2023 and the Haim Falk Award in 2024.
Tania Tanic is a senior executive with over 25 years of experience in cybersecurity, executive leadership, and technology across the financial services, banking, insurance, and professional sectors.
She is the founder and CEO of BrainStorm CyberRisk and COO of Bradley & Rollins Cyberdefense, where she guides organizations in strengthening cyber resilience, governance, and compliance while driving innovation and transformation.
She is also the creator of CYBERTACTIK, an AI-powered cyber resilience simulation platform launched globally in 2025. A CPA and Executive MBA graduate, Tania is recognized as an empathetic leader, mentor, and advocate for women in technology, as well as a strong supporter of equity, diversity, and inclusion.
Jack Martin has more than 20 years of experience leading fraud investigations, litigation support, and data-driven audit innovation.
He is proficient at using a wide variety of analytic, data mining, statistical and visualization tools, and has performed extensive work in forensic areas such as disputes and litigation support, quantification of damages and fraud investigations.
Jack has given expert testimony and has been recognized by the courts in Montreal and Quebec City as an expert in forensic accounting, forensic data analytics, and statistical sampling. Jack also teaches Auditing and IT Auditing as a part-time lecturer at the John Molson School of Business.
Steve Forte is a biotech executive with more than 25 years of finance and leadership experience. He most recently served as President, CEO and CFO of Repare Therapeutics, a NASDAQ-listed precision oncology company, where he led the company's 2020 IPO — one of the largest in Canadian biotech history, raising approximately $253 million and achieving a post-IPO market capitalization of over $1.1 billion — before being appointed CEO to lead a strategic value-realization process that culminated in the company's sale in 2026.
Earlier in his career, Steve served as CFO of Clementia Pharmaceuticals through its $1.3 billion sale to Ipsen S.A., and held senior finance leadership roles at Aptalis Pharma, including through its $2.9 billion sale to Forest Laboratories. He began his career in finance and consulting roles at PwC and Deloitte.
Steve currently serves on the Board of Directors of DCx Therapeutics and the Strategic Advisory Board of Bioneex, and previously served on the Board of Directors of Profound Medical Inc. He holds a Bachelor of Commerce in Accountancy from Concordia University's John Molson School of Business and is a member of the Quebec Order of Chartered Professional Accountants.
© Concordia University